Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas

Genome Biology

Volumn 14, Issue 12, 2013, Pages

  Renner, Marcus ^a   Wolf, Thomas ^a,b   Meyer, Hannah ^b   Hartmann, Wolfgang ^c   Penzel, Roland ^a   Ulrich, Alexis ^a   Lehner, Burkhard ^a   Hovestadt, Volker ^b   Czwan, Esteban ^b   Egerer, Gerlinde ^a   Schmitt, Thomas ^a   Alldinger, Ingo ^a   Renker, Eva K ^a   Ehemann, Volker ^a   Eils, Roland ^b,d   Wardelmann, Eva ^c   Büttner, Reinhard ^c   Lichter, Peter ^b   Brors, Benedikt ^b   Schirmacher, Peter ^a   Mechtersheimer, Gunhild ^a   more..

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA; MESSENGER RNA; MEMBRANE PROTEIN; NERVE PROTEIN; NNAT PROTEIN, HUMAN;

ARTICLE; CANCER GRADING; CDKN2A GENE; CELL MIGRATION; CELL VIABILITY; COL14A1 GENE; CPG ISLAND; DMRT2 GENE; DNA METHYLATION; FBLN2 GENE; GENE; GENE CLUSTER; GENE EXPRESSION; GENE MAPPING; GENETIC ANALYSIS; HUMAN; MYXOSARCOMA; NNAT GENE; PATHOGENESIS; PYROXD2 GENE; RNA ISOLATION; SOFT TISSUE SARCOMA; SPEG GENE; ZNF217 GENE; ALGORITHM; BIOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MOLECULAR GENETICS; PATHOLOGY; PROCEDURES; SARCOMA; TUMOR CELL LINE; CANCER CLASSIFICATION; CLUSTER ANALYSIS; CONTROLLED STUDY; DEDIFFERENTIATED LIPOSARCOMA; FIBROMYXOSARCOMA; HIGH GRADE SOFT TISSUE SARCOMA; HUMAN CELL; HUMAN TISSUE; LEIOMYOSARCOMA; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; PLEOMORPHIC LIPOSARCOMA; SYNOVIAL SARCOMA; UNDIFFERENTIATED PLEOMORPHIC SARCOMA;

ALGORITHMS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOSARCOMA, MYXOID; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; SARCOMA;

EID: 84890266248     PISSN: None     EISSN: 1474760X     Source Type: Journal    
DOI: 10.1186/gb-2013-14-12-r137     Document Type: Article

References (115)

1. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358:1148-1159. 10.1056/NEJMra072067, 18337604.
2. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011, 17:330-339.
3. Bauer AP, Leikam D, Krinner S, Notka F, Ludwig C, Langst G, Wagner R. The impact of intragenic CpG content on gene expression. Nucleic Acids Res 2010, 38:3891-3908. 10.1093/nar/gkq115, 2896515, 20203083.
4. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 2007, 16 Spec No 1:R50-R59.
5. Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, DSouza C, Fouse SD, Johnson BE, Hong C, Nielsen C, Zhao Y, Turecki G, Delaney A, Varhol R, Thiessen N, Shchors K, Heine VM, Rowitch DH, Xing X, Fiore C, Schillebeeckx M, Jones SJ, Haussler D, Marra MA, Hirst M, Wang T, Costello JF. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 2010, 466:253-257. 10.1038/nature09165, 20613842.
6. Kulis M, Heath S, Bibikova M, Queiros AC, Navarro A, Clot G, Martinez-Trillos A, Castellano G, Brun-Heath I, Pinyol M, Barberan-Soler S, Papasaikas P, Jares P, Bea S, Rico D, Ecker S, Rubio M, Royo R, Ho V, Klotzle B, Hernandez L, Conde L, Lopez-Guerra M, Colomer D, Villamor N, Aymerich M, Rozman M, Bayes M, Gut M, Gelpi JL. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 2012, 44:1236-1242. 10.1038/ng.2443, 23064414.
7. Ball MP, Li JB, Gao Y, Lee JH, LeProust EM, Park IH, Xie B, Daley GQ, Church GM. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 2009, 27:361-368. 10.1038/nbt.1533, 3566772, 19329998.
8. Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, Kim J, Aryee MJ, Ji H, Ehrlich LI, Yabuuchi A, Takeuchi A, Cunniff KC, Hongguang H, McKinney-Freeman S, Naveiras O, Yoon TJ, Irizarry RA, Jung N, Seita J, Hanna J, Murakami P, Jaenisch R, Weissleder R, Orkin SH, Weissman IL, Feinberg AP, Daley GQ. Epigenetic memory in induced pluripotent stem cells. Nature 2010, 467:285-290. 10.1038/nature09342, 3150836, 20644535.
9. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011, 469:343-349. 10.1038/nature09784, 3760771, 21248841.
10. Gonzales KA, Ng HH. Choreographing pluripotency and cell fate with transcription factors. Biochim Biophys Acta 2011, 1809:337-349. 10.1016/j.bbagrm.2011.06.009, 21722763.
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
12. Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG, Esteller M. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 2003, 63:1114-1121.
13. Smiraglia DJ, Rush LJ, Fruhwald MC, Dai Z, Held WA, Costello JF, Lang JC, Eng C, Li B, Wright FA, Caligiuri MA, Plass C. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet 2001, 10:1413-1419. 10.1093/hmg/10.13.1413, 11440994.
14. Borden EC, Baker LH, Bell RS, Bramwell V, Demetri GD, Eisenberg BL, Fletcher CD, Fletcher JA, Ladanyi M, Meltzer P, OSullivan B, Parkinson DR, Pisters PW, Saxman S, Singer S, Sundaram M, van Oosterom AT, Verweij J, Waalen J, Weiss SW, Brennan MF. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res 2003, 9:1941-1956.
15. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone 2013, Lyon: International Agency for Research on Cancer (IARC), 4.
16. van de Rijn M, Fletcher JA. Genetics of soft tissue tumors. Annu Rev Pathol 2006, 1:435-466. 10.1146/annurev.pathol.1.110304.100052, 18039122.
17. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, Evans HL. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer 2003, 97:2530-2543. 10.1002/cncr.11365, 12733153.
18. Mendenhall WM, Indelicato DJ, Scarborough MT, Zlotecki RA, Gibbs CP, Mendenhall NP, Mendenhall CM, Enneking WF. The management of adult soft tissue sarcomas. Am J Clin Oncol 2009, 32:436-442. 10.1097/COC.0b013e318173a54f, 19657238.
19. Kasper B. Standards and novel therapeutic options in the treatment of patients with soft tissue sarcoma. Rev Recent Clin Trials 2007, 2:206-211. 10.2174/157488707781662706, 18474006.
20. Adamowicz M, Radlwimmer B, Rieker RJ, Mertens D, Schwarzbach M, Schraml P, Benner A, Lichter P, Mechtersheimer G, Joos S. Frequent amplifications and abundant expression of TRIO, NKD2, and IRX2 in soft tissue sarcomas. Genes Chromosomes Cancer 2006, 45:829-838. 10.1002/gcc.20343, 16752383.
21. Francis P, Namlos HM, Muller C, Eden P, Fernebro J, Berner JM, Bjerkehagen B, Akerman M, Bendahl PO, Isinger A, Rydholm A, Myklebost O, Nilbert M. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 2007, 8:73. 10.1186/1471-2164-8-73, 1839099, 17359542.
22. Fritz B, Schubert F, Wrobel G, Schwaenen C, Wessendorf S, Nessling M, Korz C, Rieker RJ, Montgomery K, Kucherlapati R, Mechtersheimer G, Eils R, Joos S, Lichter P. Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res 2002, 62:2993-2998.
23. Renner M, Czwan E, Hartmann W, Penzel R, Brors B, Eils R, Wardelmann E, Buttner R, Lichter P, Schirmacher P, Mechtersheimer G. MicroRNA profiling of primary high-grade soft tissue sarcomas. Genes Chromosomes Cancer 2012, 51:982-996. 10.1002/gcc.21980, 22811003.
24. Subramanian S, Lui WO, Lee CH, Espinosa I, Nielsen TO, Heinrich MC, Corless CL, Fire AZ, van de Rijn M. MicroRNA expression signature of human sarcomas. Oncogene 2008, 27:2015-2026. 10.1038/sj.onc.1210836, 17922033.
25. Ugras S, Brill ER, Jacobsen A, Hafner M, Socci N, Decarolis PL, Khanin R, OConnor RB, Mihailovic A, Taylor BS, Sheridan R, Gimble J, Viale A, Crago A, Antonescu CR, Sander C, Tuschl T, Singer S. Small RNA sequencing and functional characterization reveals microRNA-143 tumor suppressor activity in liposarcoma. Cancer Res 2011, 71:5659-5669. 10.1158/0008-5472.CAN-11-0890, 3165140, 21693658.
26. Mahoney SE, Yao Z, Keyes CC, Tapscott SJ, Diede SJ. Genome-wide DNA methylation studies suggest distinct DNA methylation patterns in pediatric embryonal and alveolar rhabdomyosarcomas. Epigenetics 2012, 7:400-408. 10.4161/epi.19463, 3368822, 22419069.
27. Seidel C, Bartel F, Rastetter M, Bluemke K, Wurl P, Taubert H, Dammann R. Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. Int J Cancer 2005, 114:442-447. 10.1002/ijc.20707, 15551306.
28. Seidel C, Schagdarsurengin U, Blumke K, Wurl P, Pfeifer GP, Hauptmann S, Taubert H, Dammann R. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog 2007, 46:865-871. 10.1002/mc.20317, 17538946.
29. Sievers S, Fritzsch C, Lehnhardt M, Zahn S, Kutzner N, Kuhnen C, Muller O. Hypermethylation of the APC promoter but lack of APC mutations in myxoid/round-cell liposarcoma. Int J Cancer 2006, 119:2347-2352. 10.1002/ijc.22117, 16858687.
30. Taylor BS, DeCarolis PL, Angeles CV, Brenet F, Schultz N, Antonescu CR, Scandura JM, Sander C, Viale AJ, Socci ND, Singer S. Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. Cancer Discov 2011, 1:587-597. 10.1158/2159-8290.CD-11-0181, 3274776, 22328974.
31. Siddiqi S, Terry M, Matushansky I. Hiwi mediated tumorigenesis is associated with DNA hypermethylation. PLoS ONE 2012, 7:e33711. 10.1371/journal.pone.0033711, 3306289, 22438986.
32. Patel N, Black J, Chen X, Marcondes AM, Grady WM, Lawlor ER, Borinstein SC. DNA methylation and gene expression profiling of Ewing sarcoma primary tumors reveal genes that are potential targets of epigenetic inactivation. Sarcoma 2012, 2012:498472. 3447379, 23024594.
33. Bessarabova M, Kirillov E, Shi W, Bugrim A, Nikolsky Y, Nikolskaya T. Bimodal gene expression patterns in breast cancer. BMC Genomics 2010, 11:S8.
34. Kaufman L, Rousseeuw PJ. Finding Groups in Data: An Introduction to Cluster Analysis 2005, Wiley-Interscience.
35. Hennig C. Cluster-wise assessment of cluster stability. Comput Stat Data Anal 2007, 52:258-271.
36. Roesch-Ely M, Leipold A, Nees M, Holzinger D, Dietz A, Flechtenmacher C, Wolf T, Zapatka M, Bosch FX. Proteomic analysis of field cancerization in pharynx and oesophagus: a prospective pilot study. J Pathol 2010, 221:462-470.
37. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000, 25:25-29. 10.1038/75556, 3037419, 10802651.
38. Martin A, Ochagavia ME, Rabasa LC, Miranda J, Fernandez-de-Cossio J, Bringas R. BisoGenet: a new tool for gene network building, visualization and analysis. BMC Bioinforma 2010, 11:91.
39. von Neuhoff N, Oumeraci T, Wolf T, Kollewe K, Bewerunge P, Neumann B, Brors B, Bufler J, Wurster U, Schlegelberger B, Dengler R, Zapatka M, Petri S. Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic. PLoS ONE 2012, 7:e44401. 10.1371/journal.pone.0044401, 3435306, 22970211.
40. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 2012, 13:679-692. 10.1038/nrg3270, 22945394.
41. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002, 21:5400-5413. 10.1038/sj.onc.1205651, 12154403.
42. Feber A, Wilson GA, Zhang L, Presneau N, Idowu B, Down TA, Rakyan VK, Noon LA, Lloyd AC, Stupka E, Schiza V, Teschendorff AE, Schroth GP, Flanagan A, Beck S. Comparative methylome analysis of benign and malignant peripheral nerve sheath tumors. Genome Res 2011, 21:515-524. 10.1101/gr.109678.110, 3065699, 21324880.
43. Kawaguchi K, Oda Y, Saito T, Yamamoto H, Takahira T, Kobayashi C, Tamiya S, Tateishi N, Iwamoto Y, Tsuneyoshi M. DNA hypermethylation status of multiple genes in soft tissue sarcomas. Mod Pathol 2006, 19:106-114.
44. Antonescu CR. Molecular profiling in the diagnosis and treatment of high grade sarcomas. Ultrastruct Pathol 2008, 32:37-42. 10.1080/01913120801897174, 18446666.
45. Gibault L, Perot G, Chibon F, Bonnin S, Lagarde P, Terrier P, Coindre JM, Aurias A. New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics. J Pathol 2011, 223:64-71. 10.1002/path.2787, 21125665.
46. Olsen SH, Thomas DG, Lucas DR. Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma. Mod Pathol 2006, 19:659-668. 10.1038/modpathol.3800569, 16528378.
47. Nielsen TO, Hsu FD, OConnell JX, Gilks CB, Sorensen PH, Linn S, West RB, Liu CL, Botstein D, Brown PO, van de Rijn M. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol 2003, 163:1449-1456. 10.1016/S0002-9440(10)63502-X, 1868308, 14507652.
48. Folpe AL, Schmidt RA, Chapman D, Gown AM. Poorly differentiated synovial sarcoma: immunohistochemical distinction from primitive neuroectodermal tumors and high-grade malignant peripheral nerve sheath tumors. Am J Surg Pathol 1998, 22:673-682. 10.1097/00000478-199806000-00004, 9630174.
49. Issa JP. DNA methylation as a clinical marker in oncology. J Clin Oncol 2012, 30:2566-2568. 10.1200/JCO.2012.42.1016, 22564986.
50. Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L, Zucknick M, Mertens D, Buhler A, Oakes CC, Larson RA, Kay NE, Jelinek DF, Kipps TJ, Rassenti LZ, Gribben JG, Dohner H, Heerema NA, Marcucci G, Plass C, Byrd JC. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol 2012, 30:2483-2491. 10.1200/JCO.2011.39.3090, 3397783, 22564988.
51. Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, Saikali S, Etcheverry A, Hamlat A, Loussouarn D, Campion L, Campone M, Vallette FM, Gratas-Rabbia-Re C. Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol 2010, 97:311-322. 10.1007/s11060-009-0031-1, 19841865.
52. Ndlovu MN, Denis H, Fuks F. Exposing the DNA methylome iceberg. Trends Biochem Sci 2011, 36:381-387.
53. Rauch TA, Wu X, Zhong X, Riggs AD, Pfeifer GP. A human B cell methylome at 100-base pair resolution. Proc Natl Acad Sci USA 2009, 106:671-678. 10.1073/pnas.0812399106, 2621253, 19139413.
54. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366:704-707. 10.1038/366704a0, 8259215.
55. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell 2006, 127:265-275. 10.1016/j.cell.2006.10.003, 17055429.
56. Oda Y, Yamamoto H, Takahira T, Kobayashi C, Kawaguchi K, Tateishi N, Nozuka Y, Tamiya S, Tanaka K, Matsuda S, Yokoyama R, Iwamoto Y, Tsuneyoshi M. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis. J Pathol 2005, 207:410-421. 10.1002/path.1848, 16177957.
57. Perrone F, Tamborini E, Dagrada GP, Colombo F, Bonadiman L, Albertini V, Lagonigro MS, Gabanti E, Caramuta S, Greco A, Torre GD, Gronchi A, Pierotti MA, Pilotti S. 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations. Cancer 2005, 104:159-169. 10.1002/cncr.21113, 15929122.
58. Kawaguchi K, Oda Y, Saito T, Yamamoto H, Tamiya S, Takahira T, Miyajima K, Iwamoto Y, Tsuneyoshi M. Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis. J Pathol 2003, 201:487-495. 10.1002/path.1419, 14595762.
59. Perot G, Chibon F, Montero A, Lagarde P, de The H, Terrier P, Guillou L, Ranchere D, Coindre JM, Aurias A. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Am J Pathol 2010, 177:2080-2090. 10.2353/ajpath.2010.100104, 2947301, 20884963.
60. Endo M, Kobayashi C, Setsu N, Takahashi Y, Kohashi K, Yamamoto H, Tamiya S, Matsuda S, Iwamoto Y, Tsuneyoshi M, Oda Y. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors. Clin Cancer Res 2011, 17:3771-3782. 10.1158/1078-0432.CCR-10-2393, 21262917.
61. Haller F, Lobke C, Ruschhaupt M, Cameron S, Schulten HJ, Schwager S, von Heydebreck A, Gunawan B, Langer C, Ramadori G, Sultmann H, Poustka A, Korf U, Fuzesi L. Loss of 9p leads to p16INK4A down-regulation and enables RB/E2F1-dependent cell cycle promotion in gastrointestinal stromal tumours (GISTs). J Pathol 2008, 215:253-262. 10.1002/path.2352, 18438954.
62. Simons A, Schepens M, Jeuken J, Sprenger S, van de Zande G, Bjerkehagen B, Forus A, Weibolt V, Molenaar I, van den Berg E, Myklebost O, Bridge J, van Kessel AG, Suijkerbuijk R. Frequent loss of 9p21 (p16(INK4A)) and other genomic imbalances in human malignant fibrous histiocytoma. Cancer Genet Cytogenet 2000, 118:89-98. 10.1016/S0165-4608(99)00178-8, 10748288.
63. Law EW, Cheung AK, Kashuba VI, Pavlova TV, Zabarovsky ER, Lung HL, Cheng Y, Chua D, Lai-Wan Kwong D, Tsao SW, Sasaki T, Stanbridge EJ, Lung ML. Anti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma. Oncogene 2012, 31:728-738. 10.1038/onc.2011.272, 21743496.
64. Hill VK, Hesson LB, Dansranjavin T, Dallol A, Bieche I, Vacher S, Tommasi S, Dobbins T, Gentle D, Euhus D, Lewis C, Dammann R, Ward RL, Minna J, Maher ER, Pfeifer GP, Latif F. Identification of 5 novel genes methylated in breast and other epithelial cancers. Mol Cancer 2010, 9:51. 10.1186/1476-4598-9-51, 2841122, 20205715.
65. Vendrell JA, Thollet A, Nguyen NT, Ghayad SE, Vinot S, Bieche I, Grisard E, Josserand V, Coll JL, Roux P, Corbo L, Treilleux I, Rimokh R, Cohen PA. ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion. Cancer Res 2012, 72:3593-3606. 10.1158/0008-5472.CAN-11-3095, 22593193.
66. Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T, Yao M, Latif F, Maher ER. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 2010, 29:2104-2117. 10.1038/onc.2009.493, 3021900, 20154727.
67. Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, Wu K, Luxon BA, Sinha M, Anastasiadis PZ, Copland JA. Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS ONE 2010, 5:e10696. 10.1371/journal.pone.0010696, 2872663, 20502531.
68. Houshdaran S, Hawley S, Palmer C, Campan M, Olsen MN, Ventura AP, Knudsen BS, Drescher CW, Urban ND, Brown PO, Laird PW. DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS ONE 2010, 5:e9359. 10.1371/journal.pone.0009359, 2825254, 20179752.
69. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000, 24:227-235. 10.1038/73432, 10700174.
70. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011, 29:32-45. 10.1002/stem.563, 21280157.
71. Zhang W, Yan W, You G, Bao Z, Wang Y, Liu Y, You Y, Jiang T. Genome-wide DNA methylation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMP- primary glioblastoma. Cancer Lett 2012, 328:120-125.
72. Stratford EW, Castro R, Wennerstrom A, Holm R, Munthe E, Lauvrak S, Bjerkehagen B, Myklebost O. Liposarcoma cells with aldefluor and CD133 activity have a cancer stem cell potential. Clin Sarcoma Res 2011, 1:8. 10.1186/2045-3329-1-8, 3351708, 22612877.
73. Lohberger B, Rinner B, Stuendl N, Absenger M, Liegl-Atzwanger B, Walzer SM, Windhager R, Leithner A. Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma. PLoS ONE 2012, 7:e43664. 10.1371/journal.pone.0043664, 3426519, 22928012.
74. Timpl R, Sasaki T, Kostka G, Chu ML. Fibulins: a versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol 2003, 4:479-489. 10.1038/nrm1130, 12778127.
75. En-lin S, Sheng-guo C, Hua-qiao W. The expression of EFEMP1 in cervical carcinoma and its relationship with prognosis. Gynecol Oncol 2010, 117:417-422. 10.1016/j.ygyno.2009.12.016, 20378157.
76. Song EL, Hou YP, Yu SP, Chen SG, Huang JT, Luo T, Kong LP, Xu J, Wang HQ. EFEMP1 expression promotes angiogenesis and accelerates the growth of cervical cancer in vivo. Gynecol Oncol 2011, 121:174-180. 10.1016/j.ygyno.2010.11.004, 21163514.
77. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, Goodman GE, Thornquist MD, Liu G, de Perrot M, Tsao MS, Goparaju C. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012, 367:1417-1427. 10.1056/NEJMoa1115050, 3761217, 23050525.
78. Nomoto S, Kanda M, Okamura Y, Nishikawa Y, Qiyong L, Fujii T, Sugimoto H, Takeda S, Nakao A. Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol 2010, 17:923-932. 10.1245/s10434-009-0790-0, 19898900.
79. Tong JD, Jiao NL, Wang YX, Zhang YW, Han F. Downregulation of fibulin-3 gene by promoter methylation in colorectal cancer predicts adverse prognosis. Neoplasma 2011, 58:441-448. 10.4149/neo_2011_05_441, 21744999.
80. Wang R, Zhang YW, Chen LB. Aberrant promoter methylation of FBLN-3 gene and clinicopathological significance in non-small cell lung carcinoma. Lung Cancer 2010, 69:239-244. 10.1016/j.lungcan.2009.10.009, 19913326.
81. Kim YJ, Yoon HY, Kim SK, Kim YW, Kim EJ, Kim IY, Kim WJ. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res 2011, 17:4523-4530. 10.1158/1078-0432.CCR-10-2817, 21571867.
82. Kim EJ, Lee SY, Woo MK, Choi SI, Kim TR, Kim MJ, Kim KC, Cho EW, Kim IG. Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation. Int J Oncol 2012, 40:402-408.
83. Sadr-Nabavi A, Ramser J, Volkmann J, Naehrig J, Wiesmann F, Betz B, Hellebrand H, Engert S, Seitz S, Kreutzfeld R, Sasaki T, Arnold N, Schmutzler R, Kiechle M, Niederacher D, Harbeck N, Dahl E, Meindl A. Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer 2009, 124:1727-1735. 10.1002/ijc.24108, 19115204.
84. Seeliger H, Camaj P, Ischenko I, Kleespies A, De Toni EN, Thieme SE, Blum H, Assmann G, Jauch KW, Bruns CJ. EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res 2009, 7:189-198. 10.1158/1541-7786.MCR-08-0132, 19208748.
85. Hsieh CM, Yet SF, Layne MD, Watanabe M, Hong AM, Perrella MA, Lee ME. Genomic cloning and promoter analysis of aortic preferentially expressed gene-1. Identification of a vascular smooth muscle-specific promoter mediated by an E box motif. J Biol Chem 1999, 274:14344-14351. 10.1074/jbc.274.20.14344, 10318857.
86. Usui H, Ichikawa T, Miyazaki Y, Nagai S, Kumanishi T. Isolation of cDNA clones of the rat mRNAs expressed preferentially in the prenatal stages of brain development. Brain Res Dev Brain Res 1996, 97:185-193. 10.1016/S0165-3806(96)00152-6, 8997503.
87. Joseph R, Dou D, Tsang W. Neuronatin mRNA: alternatively spliced forms of a novel brain-specific mammalian developmental gene. Brain Res 1995, 690:92-98. 10.1016/0006-8993(95)00621-V, 7496812.
88. Aikawa S, Kato T, Elsaesser F, Kato Y. Molecular cloning of porcine neuronatin and analysis of its expression during pituitary ontogeny. Exp Clin Endocrinol Diabetes 2003, 111:475-479.
89. Revill K, Dudley KJ, Clayton RN, McNicol AM, Farrell WE. Loss of neuronatin expression is associated with promoter hypermethylation in pituitary adenoma. Endocr Relat Cancer 2009, 16:537-548. 10.1677/ERC-09-0008, 19218280.
90. Kuerbitz SJ, Pahys J, Wilson A, Compitello N, Gray TA. Hypermethylation of the imprinted NNAT locus occurs frequently in pediatric acute leukemia. Carcinogenesis 2002, 23:559-564. 10.1093/carcin/23.4.559, 11960906.
91. Evans HK, Weidman JR, Cowley DO, Jirtle RL. Comparative phylogenetic analysis of blcap/nnat reveals eutherian-specific imprinted gene. Mol Biol Evol 2005, 22:1740-1748. 10.1093/molbev/msi165, 15901842.
92. Schulz R, McCole RB, Woodfine K, Wood AJ, Chahal M, Monk D, Moore GE, Oakey RJ. Transcript- and tissue-specific imprinting of a tumour suppressor gene. Hum Mol Genet 2009, 18:118-127. 2666296, 18836209.
93. Thelin-Jarnum S, Lassen C, Panagopoulos I, Mandahl N, Aman P. Identification of genes differentially expressed in TLS-CHOP carrying myxoid liposarcomas. Int J Cancer 1999, 83:30-33. 10.1002/(SICI)1097-0215(19990924)83:1<30::AID-IJC6>3.0.CO;2-4, 10449603.
94. Suh YH, Kim WH, Moon C, Hong YH, Eun SY, Lim JH, Choi JS, Song J, Jung MH. Ectopic expression of Neuronatin potentiates adipogenesis through enhanced phosphorylation of cAMP-response element-binding protein in 3 T3-L1 cells. Biochem Biophys Res Commun 2005, 337:481-489. 10.1016/j.bbrc.2005.09.078, 16223607.
95. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004, 4:143-153. 10.1038/nrc1279, 14732866.
96. Dalal KM, Kattan MW, Antonescu CR, Brennan MF, Singer S. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg 2006, 244:381-391. 1856537, 16926564.
97. Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 2003, 238:358-370. discussion 370-351, 1422708, 14501502.
98. Xu DS, Yang C, Proescholdt M, Brundl E, Brawanski A, Fang X, Lee CS, Weil RJ, Zhuang Z, Lonser RR. Neuronatin in a subset of glioblastoma multiforme tumor progenitor cells is associated with increased cell proliferation and shorter patient survival. PLoS ONE 2012, 7:e37811. 10.1371/journal.pone.0037811, 3356299, 22624064.
99. Ryu S, McDonnell K, Choi H, Gao D, Hahn M, Joshi N, Park SM, Catena R, Do Y, Brazin J, Vahdat LT, Silver RB, Mittal V. Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration. Cancer Cell 2013, 23:63-76. 10.1016/j.ccr.2012.11.019, 23328481.
100. Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, Shen R, Gunderson KL. Genome-wide DNA methylation profiling using Infinium® assay. Epigenomics 2009, 1:177-200. 10.2217/epi.09.14, 22122642.
101. Du P, Zhang X, Huang C-C, Jafari N, Kibbe WA, Hou L, Lin SM. Comparison of beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinforma 2010, 11:587.
102. Du P, Kibbe WA, Lin S. Using Lumi, a package processing Illumina Microarray - overview of Lumi data preprocessing. Cancer 2007, 2:1-31.
103. Du P, Kibbe WA, Lin SM. nuID: a universal naming scheme of oligonucleotides for Illumina, Affymetrix, and other microarrays. Biol Direct 2007, 2:16. 10.1186/1745-6150-2-16, 1891274, 17540033.
104. R Core Team A Language and Environment for Statistical Computing 2013, Vienna, Austria: R Foundation for Statistical Computing, R Core Team.
105. Wickham H. ggplot2: elegant graphics for data analysis. Media 2009, 16:224.
106. Tibshirani R, Hastie T. Outlier sums for differential gene expression analysis. Biostatistics 2007, 8:2-8. 10.1093/biostatistics/kxl005, 16702229.
107. Abdi H. The Kendall rank correlation coefficient. Cognition 1955, 11:1-7.
108. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics 2005, 21:3940-3941. 10.1093/bioinformatics/bti623, 16096348.
109. Vanderlooy S, Hüllermeier E. A critical analysis of variants of the AUC. Mach Learn 2008, 72:247-262.
110. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 1995, 57:289-300.
111. Kursa MB, Jankowski A, Rudnicki WR. Boruta - a system for feature selection. Fundamenta Informaticae 2010, 101:271-285.
112. Kursa MB, Rudnicki WR. Feature selection with the Boruta package. J Statistical Software 2010, 36:1-13.
113. Touw WG, Bayjanov JR, Overmars L, Backus L, Boekhorst J, Wels M, Van Hijum SA. Data mining in the life sciences with random forest: a walk in the park or lost in the jungle?. Brief Bioinform 2012, bbs034.
114. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991, 139:271-279. 10.1016/0022-1759(91)90198-O, 1710634.
115. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002, 30:207-210. 10.1093/nar/30.1.207, 99122, 11752295.